Cytokines, cytokine receptors and matrix interactions control and regulate the development of the hematopoietic system, normal as well as malignant. IL-6 has been recognized to have a major role in the development of multiple myeloma, although its mode of action is unclear. Preliminary studies indicate co-existence of autocrine and paracrine IL- 6 stimulation and lead us to believe that IL-6 gene expression by myeloma cells is inducible rather than constitutive. Identifying the cytokines which induce IL-6 gene expression by myeloma cells and determining the cells which produce them is one of the goals of this project. Sensitive techniques such as PCR and ELISA will be employed and new techniques developed for single cell analysis. Although myeloma cells produce IL-6 and display IL-6 receptors, their low in vivo proliferative activity and the inability of the cytokine to induce sustained proliferation in vitro suggest that the target cell for IL-6 may be a myeloma precursor cell. To address this hypothesis, methods for purifying the pre-myeloma cells from myeloma patient's blood will be developed. High resolution flow sorting on the basis of phenotypic characteristics reported to be associated with pre-myeloma cells will be used to obtain these cells in high purity. The effects of cytokines on the proliferation and differentiation of these cells into the recognizable monoclonal myeloma cells will be studied using a variety of culture conditions, including co-cultures with cytokine secreting cells. Sophisticated cell cycle analysis techniques like BUdR/IUdR labeling and expression of the Ki-67 antigen will be used to determine proliferation. Morphologic, genetic and phenotypic analysis with the aid of image analysis will help determine differentiation. Examination of the effects of dexamethasone and interferon which are effective in the treatment of myeloma will reveal if they have regulatory effects on the production of cytokines and if resistance to these drugs is a tumor and/or an accessory cell phenomenon. These data, generated with help from the Cores, will elucidate the role of cytokines in the development of multiple myeloma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055819-04
Application #
5209153
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1996
Total Cost
Indirect Cost
Rasche, L; Alapat, D; Kumar, M et al. (2018) Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia :
Went, Molly; Sud, Amit; Försti, Asta et al. (2018) Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun 9:3707
Mehdi, Syed J; Johnson, Sarah K; Epstein, Joshua et al. (2018) Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol :
Rasche, Leo; Angtuaco, Edgardo J; Alpe, Terri L et al. (2018) The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 132:59-66
Went, M; Sud, A; Law, P J et al. (2017) Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood Cancer J 7:e573
McDonald, James E; Kessler, Marcus M; Gardner, Michael W et al. (2017) Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res 23:1981-1987
Rasche, Leo; Weinhold, Niels; Morgan, Gareth J et al. (2017) Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev 55:190-199
Rasche, L; Chavan, S S; Stephens, O W et al. (2017) Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 8:268
Jethava, Yogesh S; Mitchell, Alan; Epstein, Joshua et al. (2017) Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clin Cancer Res 23:2665-2672
Schinke, Carolina; Hoering, Antje; Wang, Hongwei et al. (2017) The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica 102:e313-e316

Showing the most recent 10 out of 290 publications